Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 8/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 8/20 | 0.53 |
| ▸ | OGFRL1 | Q5TC84 | 6/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | CDK8 | P49336 | 1/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3411849 | 0.84 | OPRM1 (0.53) | CFTRLMNAOPRM1OGFRL1OPRL1 | |
| SCHEMBL1702808 | 0.82 | OPRM1 (0.68) | CFTROPRM1OGFRL1OPRL1KMT2A | |
| SCHEMBL517410 | 0.81 | OPRM1 (0.78) | CFTRLMNAOPRM1OGFRL1OPRL1 | |
| SCHEMBL10038858 | 0.81 | OPRM1 (0.78) | CFTRLMNAOPRM1OGFRL1OPRL1 | |
| SCHEMBL10038873 | 0.81 | OPRM1 (0.78) | CFTRLMNAOPRM1OGFRL1OPRL1 | |
| SCHEMBL1702762 | 0.76 | OPRM1 (0.53) | CFTRLMNAOPRM1OGFRL1OPRL1 | |
| SCHEMBL6031806 | 0.75 | OPRM1 (0.53) | CFTRLMNAOPRM1OGFRL1OPRL1 | |
| SCHEMBL1702743 | 0.75 | OPRM1 (0.49) | OPRM1OGFRL1OPRL1KMT2AMEN1 | |
| SCHEMBL1702741 | 0.75 | OPRM1 (0.49) | OPRM1OGFRL1OPRL1KMT2AMEN1 | |
| SCHEMBL998772 | 0.74 | OPRM1 (0.53) | CFTRLMNAOPRM1OGFRL1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121691-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-04-18 | — | — | EP | claimed |
| US-20100048553-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2121691-B1 | SPIROCYCLIC CYCLOHEXANE DERIVATIVES | GRUENENTHAL GMBH (DE) | 2012-04-18 | — | — | EP | disclosed |
| US-7960404-B2 | Spirocyclic cyclohexane compounds | GRUENENTHAL GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20100048553-A1 | Spirocyclic Cyclohexane Compounds | GRUENENTHAL GMBH (DE) | 2010-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048553-A1 | Spirocyclic Cyclohexane Compounds | PKD2, PKD1, RYR1 | CFTR 274/4885LMNA 2262/4885OPRM1 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.